Atovaquone Export Market Intelligence: India's 17 Suppliers Shipping to 21 Countries — TransData Nexus 2026

Q: Who are the top atovaquone exporters from India?

The top atovaquone exporters from India are: 1. MYLAN LABORATORIES LIMITED — $934.1M (94.3% market share); 2. GLENMARK PHARMACEUTICALS LIMITED — $28.1M (2.8% market share); 3. HETERO LABS LIMITED — $22.1M (2.2% market share); 4. LUPIN LIMITED — $5.3M (0.5% market share); 5. GLENMARK PHARMACEUTICALS LTD — $797.2K (0.1% market share). Together they account for 100.0% of India's total atovaquone export value.

Q: What is the total export value of atovaquone from India?

The total export value of atovaquone from India is $990.7M USD, recorded across 437 shipment transactions from 17 active exporters to 21 destination countries. The average shipment value is $2.3M.

Q: Which countries import atovaquone from India?

India exports atovaquone to 21 countries worldwide. The top importing countries are: HUNGARY (93.7% share, $928.5M), UNITED STATES (5.0% share, $50.0M), CANADA (0.6% share, $6.1M), GERMANY (0.4% share, $4.3M), SLOVENIA (0.1% share, $677.6K). These five markets account for 99.9% of total export value.

Q: What is the HS code for atovaquone exports from India?

The primary HS code for atovaquone exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of atovaquone exports from India?

The average unit price for atovaquone exports from India is $40.71 USD per unit, with prices ranging from $0.02 to $238.72 depending on formulation, packaging, and order volume. The total market is valued at $990.7M across 437 shipments.

Q: Which ports handle atovaquone exports from India?

The primary ports for atovaquone exports from India are SAHAR AIR (18.3% of shipments), SAHAR AIR CARGO ACC (INBOM4) (14.2% of shipments), HYDERABAD ICD (INSNF6) (9.6% of shipments), NHAVA SHEVA SEA (INNSA1) (7.6% of shipments), HYDERABAD AIR (6.2% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of atovaquone?

India is one of the world's leading exporters of atovaquone due to its large base of 17 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports atovaquone to 21 countries, demonstrating 11% global market coverage.

Q: What certifications do Indian atovaquone exporters need?

Indian atovaquone exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import atovaquone from India?

There are 71 registered buyers importing atovaquone from India, spread across 21 countries. The repeat buyer rate is 57.7%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top atovaquone supplier from India?

MYLAN LABORATORIES LIMITED is the leading atovaquone exporter from India with a market share of 94.3% and total export value of $934.1M across 58 shipments. The top 5 suppliers together control 100.0% of total export value.

Suresh Sormare

Atovaquone

India Pharmaceutical Trade Intelligence

$990.7M17 Suppliers21 CountriesHS 30049099

ExportsIndia → HUNGARY93.7%India → UNITED STATES5.0%

ImportsGERMANY → India$53.1K UNITED STATES → India$34.3K

#1 Supplier: MYLAN LABORATORIES #1 Buyer: MYLAN HUNGARY

Atovaquone Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Atovaquone to the World

Between 2022 and 2026, India exported $990.7M worth of atovaquone across 437 verified shipments to 21 countries — covering 11% of world markets in the Antimalarial & Antiparasitic segment. The largest destination is HUNGARY (93.7%). MYLAN LABORATORIES LIMITED leads with a 94.3% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Atovaquone export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Atovaquone export data snapshot — $990.7M · 17 exporters · 21 countriesTransData Nexus · Indian Customs Data

Top Atovaquone Exporters from India

17 active exporters · Ranked by export value

View all 17 →

Top Atovaquone Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	MYLAN LABORATORIES LIMITED	$934.1M	58	5	94.3%
2	GLENMARK PHARMACEUTICALS LIMITED

Top Countries Importing Atovaquone from India

21 destination markets · Ranked by import value

All 21 countries →

Top Countries Importing Atovaquone from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	HUNGARY	$928.5M	93.7%
2	UNITED STATES	$50.0M	5.0%
3	CANADA	$6.1M	0.6%
4	GERMANY	$4.3M	0.4%
5	SLOVENIA	$677.6K	0.1%
6	NETHERLANDS	$235.0K	0.0%
7	UNITED KINGDOM	$233.7K	0.0%
8	SOUTH AFRICA	$209.7K	0.0%
9	TURKEY	$172.4K	0.0%
10	UNITED ARAB EMIRATES	$101.2K	0.0%

HUNGARY is India's largest atovaquone export destination, absorbing 93.7% of total exports worth $928.5M. The top 5 importing countries — HUNGARY, UNITED STATES, CANADA, GERMANY, SLOVENIA — together account for 99.9% of India's total atovaquone export value. The remaining 16 destination countries collectively receive the other 0.1%, indicating a focused distribution strategy targeting key markets.

Who Supplies Atovaquone to India?

9 origin countries · Total import value: $152.9K

India imports atovaquone from 9 countries with a combined import value of $152.9K. The largest supplier is GERMANY ($53.1K, 7 shipments), followed by UNITED STATES and CANADA. All values are from Indian Customs (DGFT) import records.

Countries Supplying Atovaquone to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	GERMANY	$53.1K	7	34.7%
2	UNITED STATES	$34.3K	13	22.5%
3	CANADA	$23.3K	1	15.3%
4	AUSTRALIA	$19.7K	2	12.9%
5	UNITED KINGDOM	$15.9K	5	10.4%
6	JAPAN	$3.7K	1	2.4%
7	IRELAND	$2.3K	2	1.5%
8	HUNGARY	$379	2	0.2%
9	CHINA	$79	1	0.1%

GERMANY is the largest supplier of atovaquone to India, accounting for 34.7% of total import value. The top 5 origin countries — GERMANY, UNITED STATES, CANADA, AUSTRALIA, UNITED KINGDOM — together supply 95.8% of India's atovaquone imports. Click any country to see detailed supplier and buyer data for that import corridor.

Atovaquone — Export Intelligence Video

Visual overview of India's atovaquone import and export market — top suppliers, destinations, pricing, and trade routes

This video covers India's atovaquone pharmaceutical import and export market — $990.7M in total trade, 17 verified manufacturers, and 21 destination countries. Data sourced from Indian Customs (DGFT) shipment records.

Regulatory Landscape — Atovaquone

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, the Food and Drug Administration (FDA) oversees the approval and regulation of pharmaceutical products, including Atovaquone. The FDA's Orange Book lists approved Abbreviated New Drug Applications (ANDAs) for generic drugs. As of March 2026, multiple ANDAs for Atovaquone have been approved, indicating a competitive generic market. Recent approvals include those granted in June 2025 and September 2025, reflecting ongoing interest and investment in this therapeutic area.

Regarding import alerts, the FDA issues these to prevent the entry of products that appear to violate regulations. As of March 2026, there are no active import alerts specifically targeting Atovaquone from Indian manufacturers, suggesting compliance with FDA standards. However, it's crucial for exporters to maintain rigorous quality control to avoid potential future alerts. The regulatory pathway for Atovaquone involves submitting an ANDA, demonstrating bioequivalence to the reference listed drug, and adhering to Current Good Manufacturing Practices (CGMP). With 17 active Indian exporters, the competitive landscape necessitates strict compliance with FDA regulations to ensure market access.

2EU & UK Regulatory Framework

In the European Union (EU) and the United Kingdom (UK), Atovaquone requires marketing authorization before it can be sold. The European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) are responsible for granting these authorizations. As of March 2026, Atovaquone has received marketing authorizations in several EU member states and the UK, indicating its recognized therapeutic value. Manufacturers must comply with EU Good Manufacturing Practice (GMP) guidelines, which ensure that products are consistently produced and controlled according to quality standards. These guidelines are harmonized across the EU and are critical for maintaining product quality and safety.

3WHO Essential Medicines & Global Standards

Atovaquone is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in addressing global health needs. The 24th edition of the list, published in September 2025, features Atovaquone, highlighting its essential role in treating specific infections. Inclusion in this list guides countries in prioritizing procurement and ensuring availability. Additionally, Atovaquone is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), which set quality standards for medicines.

4India Regulatory Classification

In India, Atovaquone is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription drug requiring a doctor's prescription for dispensation. The National Pharmaceutical Pricing Authority (NPPA) oversees drug pricing, and as of March 2026, Atovaquone is not listed under the Drug Price Control Order (DPCO), meaning it does not have a government-mandated ceiling price. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceuticals; however, Atovaquone is not currently subject to this requirement, facilitating its export process.

5Patent & Exclusivity Status

The primary patents for Atovaquone have expired, leading to the availability of generic versions in the market. This expiration has intensified competition among manufacturers and exporters, particularly from India, which has become a significant supplier of generic Atovaquone globally. The absence of active patents allows for broader market access and pricing competition, benefiting healthcare systems and patients worldwide.

6Recent Industry Developments

In May 2025, the NPPA announced a revision of the ceiling prices for several essential medicines; however, Atovaquone was not included in this list, allowing market-driven pricing to continue. In July 2025, the EMA approved a new generic version of Atovaquone, further increasing competition in the European market. In October 2025, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of Atovaquone, which may influence national procurement strategies. In December 2025, the CDSCO issued new guidelines for the export of pharmaceuticals, emphasizing the need for stringent quality control measures, which Indian exporters of Atovaquone must adhere to. In February 2026, the FDA conducted inspections of several Indian pharmaceutical manufacturing facilities, including those producing Atovaquone, to ensure compliance with CGMP standards, highlighting the importance of maintaining quality assurance in the export process.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Atovaquone

Retail & reference prices across 9 markets vs. India FOB export price of $40.71/unit

Global Price Benchmark for Atovaquone across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$2.60	USD	According to the FDA Orange Book, Malarone was approved for malaria prophylaxis and treatment in 2000.
United Kingdom	$2.00	GBP	The UK's National Health Service (NHS) includes Malarone in its drug tariff, indicating its availability and regulated pricing within the public healthcare system.
Germany	$2.20	EUR	The European Medicines Agency (EMA) has authorized Malarone for use across member states, including Germany, ensuring standardized regulatory oversight.
Australia

Supply Chain Risk Assessment — Atovaquone

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

Atovaquone, an antiprotozoal agent, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) is heavily reliant on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where approximately 70% of India's APIs are imported from China, highlighting a significant vulnerability in the pharmaceutical supply chain.

Recent disruptions have underscored this risk. In February 2025, the U.S. Food and Drug Administration (FDA) issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practice (cGMP). These violations included failures in quality control and facility maintenance, leading to the classification of certain APIs as "adulterated." Such regulatory actions can result in supply interruptions, affecting the availability of essential medications like Atovaquone.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data from 2022 to 2026 reveals a high concentration in Atovaquone exports from India. The top five exporters account for 100% of the total export value, with MYLAN LABORATORIES LIMITED alone contributing 94.3% ($934.1M USD). This monopolization poses a significant single-source risk; any operational or compliance issues within this leading exporter could disrupt the global supply chain.

Access Complete Atovaquone Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 437 transactions across 21 markets.

Request Demo View Pricing

Frequently Asked Questions — Atovaquone Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top atovaquone exporters from India?

The leading atovaquone exporters from India are MYLAN LABORATORIES LIMITED, GLENMARK PHARMACEUTICALS LIMITED, HETERO LABS LIMITED, and 7 others. MYLAN LABORATORIES LIMITED leads with 94.3% market share ($934.1M). The top 5 suppliers together control 100.0% of total export value.

What is the total export value of atovaquone from India?

The total export value of atovaquone from India is $990.7M, recorded across 437 shipments from 17 active exporters to 21 countries. The average shipment value is $2.3M.

Which countries import atovaquone from India?

India exports atovaquone to 21 countries. The top importing countries are HUNGARY (93.7%), UNITED STATES (5.0%), CANADA (0.6%), GERMANY (0.4%), SLOVENIA (0.1%), which together account for 99.9% of total export value.

What is the HS code for atovaquone exports from India?

The primary HS code for atovaquone exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Atovaquone

Atovaquone

Top Atovaquone Exporters from India

Top Countries Importing Atovaquone from India

Who Supplies Atovaquone to India?

Quick Facts

Related Antimalarial & Antiparasitic

Related Analysis

Need Details?

Atovaquone — Export Intelligence Video

Regulatory Landscape — Atovaquone

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Atovaquone

Supply Chain Risk Assessment — Atovaquone

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Atovaquone Trade Intelligence

Frequently Asked Questions — Atovaquone Exports from India

Who are the top atovaquone exporters from India?

What is the total export value of atovaquone from India?

Which countries import atovaquone from India?

What is the HS code for atovaquone exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of atovaquone exports from India?

Which ports handle atovaquone exports from India?

Why is India a leading exporter of atovaquone?

What certifications do Indian atovaquone exporters need?

How many buyers import atovaquone from India?

What is the market share of the top atovaquone exporter from India?

Analysis Methodology